secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001650664-26-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine Q4 2025 net loss $5.6M; EDIT-401 IND on track mid-2026
----------------------------------------------------------------------

- Cash $146.6M at Dec 31, 2025, down from $269.9M; runway into Q3 2027.
- Net loss Q4 2025 $5.6M ($0.06/sh) vs $45.4M ($0.55/sh) in Q4 2024.
- Full year 2025 net loss $160.1M ($1.80/sh) vs $237.1M ($2.88/sh) in 2024.
- Lead candidate EDIT-401 achieved >90% mean LDL-C reduction in preclinical; IND/CTA submission expected by mid-2026.
- First-in-human trial in HeFH planned for 2026; early proof-of-concept data targeted by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000013/0001650664-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000013/edit-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001650664-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer